<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="alternate" hreflang="tr" href="https://uzunyasa.com/pages/blog/oral-wegovy-fda-onayi-ilk-glp1-hapi.html">
<link rel="alternate" hreflang="x-default" href="https://uzunyasa.com/pages/blog/oral-wegovy-fda-onayi-ilk-glp1-hapi.html">
<meta http-equiv="Content-Language" content="tr">
<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
<script>if(location.protocol!=="https:"&&location.hostname!=="localhost"&&location.hostname!=="127.0.0.1")location.replace("https://"+location.host+location.pathname+location.search+location.hash);</script>
<meta http-equiv="Content-Security-Policy" content="upgrade-insecure-requests">
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());
 gtag('config', 'G-QBM7E0EHFP');
</script>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Oral Wegovy FDA OnayÄ±: Ä°lk GLP-1 Kilo Verme HapÄ± Piyasada! | UzunYaÅŸa</title>
<meta name="description" content="FDA, oral semaglutid'i (Oral Wegovy) kronik kilo yÃ¶netimi iÃ§in onayladÄ±. Ä°lk GLP-1 hapÄ± olarak tarih yazan ilaÃ§, OASIS 4 Ã§alÄ±ÅŸmasÄ±nda %13.6 kilo kaybÄ± saÄŸladÄ±. Ä°ÄŸnesiz obezite tedavisi Ã§aÄŸÄ± baÅŸlÄ±yor.">
<meta name="author" content="UzunYaÅŸa">
<meta name="keywords" content="oral wegovy, oral semaglutid, GLP-1 hapÄ±, kilo verme hapÄ±, FDA onayÄ±, OASIS 4, Novo Nordisk, obezite tedavisi, iÄŸnesiz GLP-1, oral GLP-1 agonisti">
<link rel="canonical" href="https://uzunyasa.com/pages/blog/oral-wegovy-fda-onayi-ilk-glp1-hapi.html">
<!-- Open Graph -->
<meta property="og:title" content="Oral Wegovy FDA OnayÄ±: Ä°lk GLP-1 Kilo Verme HapÄ± Piyasada!">
<meta property="og:description" content="FDA oral semaglutid'i onayladÄ±. OASIS 4'te %13.6 kilo kaybÄ±. Ä°ÄŸnesiz GLP-1 Ã§aÄŸÄ± baÅŸlÄ±yor.">
<meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
<meta property="og:url" content="https://uzunyasa.com/pages/blog/oral-wegovy-fda-onayi-ilk-glp1-hapi.html">
<meta property="og:type" content="article">
<meta property="og:locale" content="tr_TR">
<meta property="article:published_time" content="2026-02-21">
<!-- Fonts -->
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800&family=Playfair+Display:wght@400;500;600;700&display=swap" rel="stylesheet">
<!-- Styles -->
<link rel="preload" href="../../styles/main.css" as="style">
 <link rel="stylesheet" href="../../styles/main.css">
<link rel="stylesheet" href="../../styles/content-page.css">
<link rel="preload" href="../../styles/animations.css" as="style">
 <link rel="stylesheet" href="../../styles/animations.css">
<style>
/* ===== READING PROGRESS BAR ===== */
.blog-progress {
  position: fixed; top: 0; left: 0; width: 0%;
  height: 3px; z-index: 10001;
  background: linear-gradient(90deg, #EC4899, #F472B6, #E8963E);
  transition: width 0.1s linear;
}

/* ===== BLOG HERO ===== */
.blog-hero {
  position: relative;
  min-height: 480px;
  display: flex;
  align-items: flex-end;
  overflow: hidden;
  margin-top: 70px;
}
.blog-hero-img {
  position: absolute; top: 0; left: 0; width: 100%; height: 100%;
  object-fit: cover;
}
.blog-hero-overlay {
  position: absolute; top: 0; left: 0; width: 100%; height: 100%;
  background: linear-gradient(180deg,
    rgba(60,30,80,0.3) 0%,
    rgba(50,25,70,0.55) 40%,
    rgba(30,15,50,0.88) 100%);
}
.blog-hero-content {
  position: relative; z-index: 2;
  max-width: 860px; margin: 0 auto;
  padding: 3rem 2rem 3.5rem;
  color: white;
}
.blog-hero-badge {
  display: inline-block;
  padding: 0.4rem 1rem;
  border-radius: 20px;
  font-size: 0.8rem; font-weight: 600;
  margin-bottom: 1.25rem;
  background: #EC4899;
  color: white;
}
.blog-hero-title {
  font-family: 'Playfair Display', serif;
  font-size: clamp(2rem, 4vw, 2.8rem);
  font-weight: 600;
  line-height: 1.2;
  margin-bottom: 1rem;
  text-shadow: 0 2px 8px rgba(0,0,0,0.3);
}
.blog-hero-subtitle {
  font-size: 1.15rem;
  opacity: 0.9;
  max-width: 640px;
  line-height: 1.7;
  margin-bottom: 1.25rem;
}
.blog-hero-meta {
  display: flex; gap: 1.5rem; flex-wrap: wrap;
  font-size: 0.85rem; opacity: 0.8;
}
.blog-hero-meta span { display: flex; align-items: center; gap: 0.4rem; }

/* ===== ARTICLE BODY ===== */
.blog-article {
  max-width: 800px;
  margin: 0 auto;
  padding: 2.5rem 2rem 4rem;
}

/* ===== BREADCRUMB ===== */
.blog-breadcrumb {
  display: flex; align-items: center; gap: 0.5rem;
  font-size: 0.85rem; color: var(--text-light);
  margin-bottom: 2rem; flex-wrap: wrap;
}
.blog-breadcrumb a {
  color: var(--primary); text-decoration: none; font-weight: 500;
}
.blog-breadcrumb a:hover { text-decoration: underline; }

/* ===== TOC ===== */
.blog-toc {
  background: linear-gradient(135deg, #fdf2f8, #fce7f3);
  border: 1px solid #f9a8d4;
  border-left: 4px solid #EC4899;
  border-radius: 0 16px 16px 0;
  padding: 1.75rem 2rem;
  margin-bottom: 2.5rem;
}
.blog-toc h4 {
  font-size: 0.9rem; font-weight: 700;
  text-transform: uppercase; letter-spacing: 0.06em;
  color: #EC4899; margin-bottom: 1rem;
}
.blog-toc ol {
  list-style: none; counter-reset: toc; margin: 0; padding: 0;
}
.blog-toc li { counter-increment: toc; margin-bottom: 0.4rem; }
.blog-toc li a {
  display: flex; align-items: center; gap: 0.6rem;
  text-decoration: none; color: #334155;
  font-size: 0.95rem; padding: 0.4rem 0.6rem;
  border-radius: 8px; transition: all 0.2s;
}
.blog-toc li a::before {
  content: counter(toc);
  display: inline-flex; align-items: center; justify-content: center;
  width: 26px; height: 26px;
  background: #fce7f3; border-radius: 50%;
  font-size: 0.75rem; font-weight: 700; color: #BE185D;
  flex-shrink: 0; transition: all 0.2s;
}
.blog-toc li a:hover { background: rgba(236,72,153,0.08); color: #EC4899; }
.blog-toc li a:hover::before { background: #EC4899; color: white; }

/* ===== CONTENT STYLES ===== */
.blog-content p {
  font-size: 1.05rem; line-height: 1.8; margin-bottom: 1.5rem; color: var(--text-dark);
}
.blog-content h2 {
  font-size: 1.5rem; font-weight: 700; color: var(--primary);
  margin: 3rem 0 1.25rem; padding-top: 2rem;
  border-top: 1px solid var(--border);
  position: relative; padding-bottom: 0.75rem;
}
.blog-content h2::after {
  content: ''; position: absolute; bottom: 0; left: 0;
  width: 60px; height: 3px;
  background: linear-gradient(90deg, #EC4899, #10b981);
  border-radius: 2px;
}
.blog-content h2:first-of-type { border-top: none; padding-top: 0; margin-top: 0; }
.blog-content h3 {
  font-size: 1.2rem; font-weight: 600; margin: 2rem 0 0.75rem; color: var(--text-dark);
}
.blog-content ul, .blog-content ol {
  margin: 1.25rem 0; padding-left: 1.5rem;
}
.blog-content li { margin-bottom: 0.5rem; font-size: 1.02rem; line-height: 1.7; }
.blog-content strong { color: var(--text-dark); }
.blog-content a { color: var(--primary); text-decoration: underline; }

/* ===== INFO BOXES ===== */
.blog-box {
  padding: 1.5rem 1.75rem;
  border-radius: 0 14px 14px 0;
  margin: 2rem 0;
  border-left: 4px solid;
  position: relative;
  display: flex; gap: 1rem; align-items: flex-start;
}
.blog-box .box-icon {
  flex-shrink: 0; width: 28px; height: 28px; margin-top: 2px;
}
.blog-box .box-body { flex: 1; }
.blog-box .box-body strong { display: block; margin-bottom: 0.4rem; font-size: 0.95rem; }
.blog-box .box-body p, .blog-box .box-body ul { margin: 0; font-size: 0.95rem; line-height: 1.7; }
.blog-box .box-body ul { padding-left: 1.2rem; margin-top: 0.5rem; }
.blog-box .box-body li { margin-bottom: 0.3rem; }

.blog-box.info {
  background: linear-gradient(135deg, #eff6ff, #f0f9ff);
  border-left-color: #3B82F6;
}
.blog-box.info .box-icon { color: #3B82F6; }
.blog-box.warning {
  background: linear-gradient(135deg, #fef3c7, #fffbeb);
  border-left-color: #F59E0B;
}
.blog-box.warning .box-icon { color: #F59E0B; }
.blog-box.success {
  background: linear-gradient(135deg, #ecfdf5, #f0fdf4);
  border-left-color: #10B981;
}
.blog-box.success .box-icon { color: #10B981; }
.blog-box.danger {
  background: linear-gradient(135deg, #fef2f2, #fee2e2);
  border-left-color: #EF4444;
}
.blog-box.danger .box-icon { color: #EF4444; }
.blog-box.tip {
  background: linear-gradient(135deg, #f0fdfa, #ecfdf5);
  border-left-color: #0D7377;
}
.blog-box.tip .box-icon { color: #0D7377; }
.blog-box.purple {
  background: linear-gradient(135deg, #f5f3ff, #ede9fe);
  border-left-color: #8B5CF6;
}
.blog-box.purple .box-icon { color: #8B5CF6; }
.blog-box.pink {
  background: linear-gradient(135deg, #fdf2f8, #fce7f3);
  border-left-color: #EC4899;
}
.blog-box.pink .box-icon { color: #EC4899; }

/* ===== KEY STAT BOX ===== */
.key-stat {
  display: flex; align-items: center; gap: 1.5rem;
  padding: 1.75rem 2rem;
  border-radius: 0 16px 16px 0;
  margin: 2rem 0;
  border-left: 5px solid var(--primary);
  background: linear-gradient(135deg, #f0fdfa, #ecfdf5);
}
.key-stat .ks-num {
  font-size: 2.75rem; font-weight: 800; color: var(--primary);
  line-height: 1; white-space: nowrap;
}
.key-stat .ks-text { font-size: 0.95rem; color: #195157; line-height: 1.6; }
.key-stat.accent { border-left-color: #E8963E; background: linear-gradient(135deg, #fffbeb, #fef3c7); }
.key-stat.accent .ks-num { color: #E8963E; }
.key-stat.danger { border-left-color: #EF4444; background: linear-gradient(135deg, #fef2f2, #fee2e2); }
.key-stat.danger .ks-num { color: #EF4444; }
.key-stat.purple { border-left-color: #8B5CF6; background: linear-gradient(135deg, #f5f3ff, #ede9fe); }
.key-stat.purple .ks-num { color: #8B5CF6; }
.key-stat.pink { border-left-color: #EC4899; background: linear-gradient(135deg, #fdf2f8, #fce7f3); }
.key-stat.pink .ks-num { color: #EC4899; }

/* ===== STAT CARDS ===== */
.stat-cards {
  display: grid;
  grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
  gap: 1rem; margin: 2rem 0;
}
.stat-card {
  background: white;
  border: 1px solid var(--border);
  border-radius: 16px;
  padding: 1.5rem;
  text-align: center;
  transition: all 0.3s ease;
  position: relative; overflow: hidden;
}
.stat-card::before {
  content: ''; position: absolute; top: 0; left: 0; right: 0;
  height: 3px;
  background: linear-gradient(90deg, #EC4899, var(--accent));
}
.stat-card:hover { transform: translateY(-4px); box-shadow: 0 12px 30px rgba(0,0,0,0.1); }
.stat-card .sc-num {
  font-size: 2rem; font-weight: 800; color: #EC4899;
  margin-bottom: 0.25rem;
}
.stat-card .sc-label {
  font-size: 0.8rem; color: var(--text-light); line-height: 1.4;
}

/* ===== COMPARISON TABLE ===== */
.blog-table {
  width: 100%; border-collapse: collapse; margin: 2rem 0;
  font-size: 0.95rem; border-radius: 12px; overflow: hidden;
  border: 1px solid var(--border);
}
.blog-table th {
  background: linear-gradient(135deg, #fdf2f8, #fce7f3);
  padding: 1rem; text-align: left; font-weight: 600;
  color: #EC4899; border-bottom: 2px solid #EC4899;
}
.blog-table td {
  padding: 0.85rem 1rem; border-bottom: 1px solid var(--border);
}
.blog-table tr:hover td { background: rgba(236,72,153,0.03); }
.blog-table tr:last-child td { border-bottom: none; }

/* ===== PULL QUOTE ===== */
.blog-quote {
  position: relative;
  padding: 2rem 2.5rem;
  margin: 2.5rem 0;
  font-size: 1.15rem; font-style: italic;
  color: #334155; line-height: 1.7;
  background: linear-gradient(135deg, #fdf2f8, #fce7f3);
  border-radius: 16px;
  border-left: 4px solid #EC4899;
}
.blog-quote::before {
  content: '\201C'; position: absolute; top: -8px; left: 16px;
  font-size: 4rem; color: rgba(236,72,153,0.15);
  font-family: Georgia, serif; line-height: 1;
}
.blog-quote cite {
  display: block; margin-top: 0.75rem;
  font-size: 0.9rem; font-style: normal;
  font-weight: 600; color: #EC4899;
}

/* ===== KEY TAKEAWAY ===== */
.blog-takeaway {
  background: linear-gradient(135deg, #195157, #2a6b73);
  color: white; padding: 2rem; border-radius: 16px;
  margin: 2.5rem 0; position: relative; overflow: hidden;
}
.blog-takeaway::before {
  content: ''; position: absolute; top: -30%; right: -10%;
  width: 200px; height: 200px;
  background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%);
  pointer-events: none;
}
.blog-takeaway h4 {
  font-size: 0.85rem; text-transform: uppercase;
  letter-spacing: 0.1em; opacity: 0.8; margin-bottom: 0.75rem;
}
.blog-takeaway ul { list-style: none; padding: 0; margin: 0; }
.blog-takeaway li {
  padding: 0.5rem 0 0.5rem 1.75rem; position: relative;
  font-size: 0.95rem; line-height: 1.6;
}
.blog-takeaway li::before {
  content: '\2713'; position: absolute; left: 0;
  color: #10b981; font-weight: 700;
}

/* ===== CTA BOX ===== */
.blog-cta {
  background: linear-gradient(135deg, var(--primary), #2a7d83);
  color: white; padding: 2.5rem; border-radius: 20px;
  text-align: center; margin: 3rem 0;
  position: relative; overflow: hidden;
}
.blog-cta::before {
  content: ''; position: absolute; top: -50%; right: -30%;
  width: 300px; height: 300px;
  background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%);
  pointer-events: none;
}
.blog-cta h3 { font-size: 1.5rem; font-weight: 700; margin-bottom: 0.75rem; }
.blog-cta p { opacity: 0.9; margin-bottom: 1.5rem; max-width: 400px; margin-left: auto; margin-right: auto; }
.blog-cta a {
  display: inline-block;
  background: white; color: var(--primary);
  padding: 0.875rem 2rem; border-radius: 10px;
  text-decoration: none; font-weight: 700; font-size: 1rem;
  transition: all 0.3s;
}
.blog-cta a:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 25px rgba(0,0,0,0.2);
}

/* ===== AUTHOR BOX ===== */
.blog-author {
  display: flex; align-items: center; gap: 1.25rem;
  padding: 1.75rem; background: white;
  border-radius: 16px; border: 1px solid var(--border);
  margin: 2.5rem 0;
  box-shadow: 0 2px 8px rgba(0,0,0,0.04);
}
.blog-author-avatar {
  width: 64px; height: 64px; border-radius: 50%;
  background: linear-gradient(135deg, #EC4899, #F472B6);
  display: flex; align-items: center; justify-content: center;
  color: white; font-weight: 700; font-size: 1.1rem;
  flex-shrink: 0;
}
.blog-author-info h4 { font-weight: 600; margin-bottom: 0.25rem; font-size: 1rem; }
.blog-author-info p { font-size: 0.85rem; color: var(--text-light); margin: 0; line-height: 1.5; }

/* ===== RELATED POSTS ===== */
.blog-related { margin: 3rem 0; }
.blog-related h3 {
  font-size: 1.25rem; font-weight: 700; color: var(--text-dark);
  margin-bottom: 1.5rem;
}
.related-grid {
  display: grid; grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));
  gap: 1.25rem;
}
.related-card {
  background: white; border: 1px solid var(--border);
  border-radius: 14px; overflow: hidden;
  text-decoration: none; color: inherit;
  transition: all 0.3s ease;
}
.related-card:hover {
  transform: translateY(-4px);
  box-shadow: 0 12px 30px rgba(0,0,0,0.1);
  border-color: #EC4899;
}
.related-card-img {
  height: 140px; background-size: cover; background-position: center;
  position: relative;
}
.related-card-img::after {
  content: ''; position: absolute; bottom: 0; left: 0; right: 0;
  height: 50%;
  background: linear-gradient(to top, rgba(0,0,0,0.4), transparent);
}
.related-card-body { padding: 1rem 1.25rem; }
.related-card-body h4 {
  font-size: 0.95rem; font-weight: 600; line-height: 1.4;
  margin-bottom: 0.5rem; color: var(--text-dark);
}
.related-card-body p {
  font-size: 0.8rem; color: var(--text-light); margin: 0;
}

/* ===== SOCIAL SHARING ===== */
.blog-share {
  display: flex; align-items: center; gap: 0.75rem;
  margin: 2rem 0; padding: 1.25rem 0;
  border-top: 1px solid var(--border);
  border-bottom: 1px solid var(--border);
}
.blog-share span { font-size: 0.9rem; font-weight: 600; color: var(--text-medium); }
.share-btn {
  display: inline-flex; align-items: center; justify-content: center;
  width: 40px; height: 40px; border-radius: 50%;
  border: 1px solid var(--border); background: white;
  color: var(--text-medium); text-decoration: none;
  transition: all 0.2s; cursor: pointer;
}
.share-btn:hover { border-color: #EC4899; color: #EC4899; background: rgba(236,72,153,0.05); }
.share-btn svg { width: 18px; height: 18px; }

/* ===== NEWSLETTER ===== */
.blog-newsletter {
  background: linear-gradient(135deg, var(--bg-cream), #fdf2f8);
  border: 2px solid var(--border);
  border-radius: 20px;
  padding: 2.5rem;
  text-align: center;
  margin: 3rem 0;
}
.blog-newsletter h3 {
  font-size: 1.3rem; font-weight: 700; color: var(--text-dark);
  margin-bottom: 0.5rem;
}
.blog-newsletter p {
  color: var(--text-medium); margin-bottom: 1.5rem; font-size: 0.95rem;
}
.newsletter-form {
  display: flex; max-width: 420px; margin: 0 auto; gap: 0.5rem;
}
.newsletter-form input {
  flex: 1; padding: 0.875rem 1rem;
  border: 1px solid var(--border); border-radius: 10px;
  font-size: 0.95rem; font-family: inherit;
}
.newsletter-form input:focus {
  outline: none; border-color: #EC4899;
  box-shadow: 0 0 0 3px rgba(236,72,153,0.1);
}
.newsletter-form button {
  background: #EC4899; color: white;
  padding: 0.875rem 1.5rem; border: none; border-radius: 10px;
  font-weight: 600; font-size: 0.95rem; cursor: pointer;
  transition: all 0.2s; font-family: inherit;
}
.newsletter-form button:hover {
  background: #DB2777;
  transform: translateY(-1px);
}

/* ===== DISCLAIMER ===== */
.blog-disclaimer {
  font-size: 0.8rem; color: var(--text-light);
  margin-top: 2rem; padding-top: 1.5rem;
  border-top: 1px solid var(--border);
  line-height: 1.6;
}

/* ===== RESPONSIVE ===== */
@media (max-width: 768px) {
  .blog-hero { min-height: 380px; }
  .blog-hero-title { font-size: 1.8rem; }
  .blog-hero-content { padding: 2rem 1.5rem 2.5rem; }
  .blog-article { padding: 2rem 1.25rem 3rem; }
  .key-stat { flex-direction: column; text-align: center; padding: 1.5rem; }
  .key-stat .ks-num { font-size: 2rem; }
  .blog-author { flex-direction: column; text-align: center; }
  .stat-cards { grid-template-columns: repeat(2, 1fr); }
  .newsletter-form { flex-direction: column; }
  .related-grid { grid-template-columns: 1fr; }
  .blog-share { flex-wrap: wrap; }
}
</style>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "Oral Wegovy FDA OnayÄ±: Ä°lk GLP-1 Kilo Verme HapÄ± Piyasada! | UzunYaÅŸa",
  "description": "FDA, oral semaglutid",
  "author": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "url": "https://uzunyasa.com"
  },
  "publisher": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://uzunyasa.com/images/logo-icon-new.png"
    }
  },
  "datePublished": "2026-02-21",
  "dateModified": "2026-02-24",
  "mainEntityOfPage": "https://uzunyasa.com/pages/blog/oral-wegovy-fda-onayi-ilk-glp1-hapi.html",
  "image": "https://uzunyasa.com/images/og-default.png"
}
</script>
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:site" content="@uzunyasaorg">
    <meta name="twitter:title" content="Oral Wegovy FDA OnayÄ±: Ä°lk GLP-1 Kilo Verme HapÄ± Piyasada!">
    <meta name="twitter:description" content="FDA oral semaglutid">
    <meta name="twitter:image" content="https://uzunyasa.com/images/og-default.png">
  </head>
<body>

<!-- Reading Progress Bar -->
<div class="blog-progress" id="blogProgress"></div>

<!-- HEADER -->
<header class="header">
  <div class="header-inner">
    <a href="../../index.html" class="logo">
      <img src="/images/logo-new.png" alt="UzunYaÅŸa" class="logo-img">
    </a>
    <nav class="nav">
      <ul class="nav-links">
        <li class="nav-dropdown">
          <a href="#" class="nav-link">KeÅŸfet</a>
          <div class="nav-dropdown-content">
            <a href="../beslenme.html" class="nav-dropdown-item">Beslenme</a>
            <a href="../egzersiz.html" class="nav-dropdown-item">Egzersiz</a>
            <a href="../tedavi.html" class="nav-dropdown-item">Kilo YÃ¶netimi</a>
            <a href="../uyku-stres.html" class="nav-dropdown-item">Zihin &amp; DavranÄ±ÅŸ</a>
          </div>
        </li>
        <li><a href="../blog.html" class="nav-link active">Blog</a></li>
        <li><a href="../araclar.html" class="nav-link">AraÃ§lar</a></li>
        <li><a href="../hikayeler.html" class="nav-link">Hikayeler</a></li>
        <li><a href="../bilim.html" class="nav-link">Bilim</a></li>
        <li><a href="../hakkimizda.html" class="nav-link">HakkÄ±mÄ±zda</a></li>
      </ul>
      <a href="../test.html" class="btn btn-primary">Teste BaÅŸla</a>
    </nav>
  </div>
</header>

<!-- HERO -->
<section class="blog-hero">
  <img class="blog-hero-img" src="https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&q=80" alt="Ä°laÃ§ hapÄ± ve tÄ±bbi tedavi konsepti">
  <div class="blog-hero-overlay"></div>
  <div class="blog-hero-content anim-slide-up anim-visible">
    <span class="blog-hero-badge">ğŸ’Š Tedavi</span>
    <h1 class="blog-hero-title">Oral Wegovy FDA OnayÄ±: Ä°lk GLP-1 Kilo Verme HapÄ± Piyasada!</h1>
    <p class="blog-hero-subtitle">FDA, oral semaglutid'i kronik kilo yÃ¶netimi iÃ§in onayladÄ±. ArtÄ±k haftada bir iÄŸne yerine gÃ¼nde bir hap yeterli. Ä°ÄŸnesiz GLP-1 Ã§aÄŸÄ± resmen baÅŸlÄ±yor.</p>
    <div class="blog-hero-meta">
      <span>ğŸ“… 21 Åubat 2026</span>
      <span>â±ï¸ 8 dk okuma</span>
      <span>ğŸ’Š UzunYaÅŸa EditÃ¶ryal</span>
    </div>
  </div>
</section>

<!-- ARTICLE -->
<article class="blog-article">

  <!-- Breadcrumb -->
  <nav class="blog-breadcrumb" aria-label="Breadcrumb">
    <a href="../../index.html">Ana Sayfa</a>
    <span>&rsaquo;</span>
    <a href="../blog.html">Blog</a>
    <span>&rsaquo;</span>
    <span>Oral Wegovy FDA OnayÄ±</span>
  </nav>

  <!-- Table of Contents -->
  <div class="blog-toc anim-slide-up">
    <h4>Ä°Ã§indekiler</h4>
    <ol>
      <li><a href="#bolum-1">Tarihi Bir Onay: Ä°lk GLP-1 Kilo Verme HapÄ±</a></li>
      <li><a href="#bolum-2">OASIS 4 Ã‡alÄ±ÅŸmasÄ±: Veriler Ne Diyor?</a></li>
      <li><a href="#bolum-3">Ä°ÄŸneden Hapa: Neden Bu Kadar Ã–nemli?</a></li>
      <li><a href="#bolum-4">GLP-1 Ä°laÃ§larÄ± KarÅŸÄ±laÅŸtÄ±rmasÄ±: Hap mÄ±, Ä°ÄŸne mi?</a></li>
      <li><a href="#bolum-5">Piyasada Ä°lk Ay: GÃ¼Ã§lÃ¼ Talep Sinyali</a></li>
      <li><a href="#bolum-6">TÃ¼rkiye Ä°Ã§in Ne Anlama Geliyor?</a></li>
      <li><a href="#bolum-7">SonuÃ§: Obezite Tedavisinde Yeni Bir Sayfa</a></li>
    </ol>
  </div>

  <!-- Content -->
  <div class="blog-content">

    <h2 id="bolum-1">Tarihi Bir Onay: Ä°lk GLP-1 Kilo Verme HapÄ±</h2>

    <p>ABD GÄ±da ve Ä°laÃ§ Dairesi (FDA), Åubat 2026'da Ã¶nemli bir onay kararÄ± verdi: <strong>Oral semaglutid (Oral Wegovy), kronik kilo yÃ¶netimi endikasyonuyla onaylanan ilk GLP-1 reseptÃ¶r agonisti hap</strong> oldu. Oral semaglutid daha Ã¶nce tip 2 diyabet tedavisi iÃ§in Rybelsus adÄ±yla (2019) onaylanmÄ±ÅŸtÄ±; ancak bu, obezite/kilo yÃ¶netimi endikasyonu iÃ§in ilk oral GLP-1 onayÄ±dÄ±r.</p>

    <p>Novo Nordisk tarafÄ±ndan geliÅŸtirilen Oral Wegovy, daha Ã¶nce yalnÄ±zca haftalÄ±k enjeksiyon formunda (Wegovy kalem) sunulan semaglutid'in gÃ¼nde bir kez aÄŸÄ±zdan alÄ±nan tablet versiyonudur. FDA'nÄ±n bu onayÄ±, obezite veya kiloya baÄŸlÄ± en az bir komorbidite (tip 2 diyabet, hipertansiyon, dislipidemi vb.) bulunan yetiÅŸkin hastalarda kullanÄ±m iÃ§in verilmiÅŸtir.</p>

    <div class="key-stat pink anim-slide-up">
      <span class="ks-num">1.</span>
      <span class="ks-text">Oral Wegovy, FDA tarafÄ±ndan kronik kilo yÃ¶netimi iÃ§in onaylanan <strong>ilk ve tek GLP-1 reseptÃ¶r agonisti hap</strong>. Bu, milyonlarca iÄŸne fobisi olan hasta iÃ§in tedaviye eriÅŸimi kÃ¶kten deÄŸiÅŸtirebilir.</span>
    </div>

    <p>GLP-1 reseptÃ¶r agonistleri â€” semaglutid (Ozempic, Wegovy) ve tirzepatid (Mounjaro, Zepbound) â€” obezite tedavisinde gÃ¼Ã§lÃ¼ kanÄ±tlarla desteklenen ilaÃ§ sÄ±nÄ±fÄ±dÄ±r. Ancak kilo yÃ¶netimi endikasyonlu tÃ¼m formlar subkutan (deri altÄ±) enjeksiyon gerektiriyordu. Ä°ÄŸne korkusu, uygulama zorluÄŸu ve hasta uyumu gibi engeller, tedaviye eriÅŸimi sÄ±nÄ±rlayan faktÃ¶rler arasÄ±ndaydÄ±.</p>

    <h2 id="bolum-2">OASIS 4 Ã‡alÄ±ÅŸmasÄ±: Veriler Ne Diyor?</h2>

    <p>FDA'nÄ±n onay kararÄ±, bÃ¼yÃ¼k Ã¶lÃ§Ã¼de <strong>OASIS 4 (Oral Semaglutide â€” Assessing Sustained Impact on weight loss in overweight/obeSe adults)</strong> klinik Ã§alÄ±ÅŸmasÄ±nÄ±n sonuÃ§larÄ±na dayanÄ±yor. Bu Faz 3 Ã§alÄ±ÅŸma, oral semaglutid'in kilo yÃ¶netimindeki etkinliÄŸini ve gÃ¼venliÄŸini deÄŸerlendirdi.</p>

    <div class="stat-cards anim-slide-up">
      <div class="stat-card"><div class="sc-num">%13.6</div><div class="sc-label">Ortalama kilo kaybÄ± (64 hafta)</div></div>
      <div class="stat-card"><div class="sc-num">64</div><div class="sc-label">HaftalÄ±k Ã§alÄ±ÅŸma sÃ¼resi</div></div>
      <div class="stat-card"><div class="sc-num">1x</div><div class="sc-label">GÃ¼nde tek doz tablet</div></div>
      <div class="stat-card"><div class="sc-num">FDA</div><div class="sc-label">Tam onay statÃ¼sÃ¼</div></div>
    </div>

    <p>OASIS 4 Ã§alÄ±ÅŸmasÄ±nÄ±n temel bulgularÄ±:</p>

    <ul>
      <li><strong>Birincil sonlanÄ±m noktasÄ± karÅŸÄ±landÄ±:</strong> Oral semaglutid alan hastalar, 64 hafta sonunda ortalama <strong>%13.6 vÃ¼cut aÄŸÄ±rlÄ±ÄŸÄ± kaybÄ±</strong> gÃ¶sterdi ğŸŸ¢ (OASIS 4, Faz 3 RKÃ‡) â€” plasebo grubunda bu oran yalnÄ±zca %2.2 idi</li>
      <li><strong>Klinik anlamlÄ± kilo kaybÄ±:</strong> HastalarÄ±n bÃ¼yÃ¼k Ã§oÄŸunluÄŸu â‰¥%5 kilo kaybÄ± eÅŸiÄŸini aÅŸtÄ±; Ã¶nemli bir kÄ±smÄ± â‰¥%10 ve â‰¥%15 eÅŸiklerine de ulaÅŸtÄ±</li>
      <li><strong>Metabolik parametrelerde iyileÅŸme:</strong> Bel Ã§evresi, HbA1c, kan basÄ±ncÄ± ve lipid profilinde anlamlÄ± dÃ¼zelme gÃ¶zlendi</li>
      <li><strong>GÃ¼venlik profili:</strong> Yan etkiler enjektabl formla benzer â€” en sÄ±k gastrointestinal ÅŸikayetler (bulantÄ±, ishal, kabÄ±zlÄ±k) bildirildi; Ã§oÄŸu hafif-orta ÅŸiddette ve geÃ§ici</li>
    </ul>

    <blockquote class="blog-quote anim-slide-up">
      OASIS 4 Ã§alÄ±ÅŸmasÄ±, oral semaglutid'in kronik kilo yÃ¶netiminde enjeksiyon formuna yakÄ±n etkinlik sunduÄŸunu, hasta uyumunu artÄ±rma potansiyeliyle birlikte ortaya koymuÅŸtur. Bu, obezite tedavisinde Ã¶nemli bir dÃ¶nÃ¼m noktasÄ±dÄ±r.
      <cite>â€” Applied Clinical Trials, Åubat 2026</cite>
    </blockquote>

    <h3>Enjeksiyon Formuyla KarÅŸÄ±laÅŸtÄ±rma</h3>

    <p>Enjektabl Wegovy (2.4 mg haftalÄ±k) ile yapÄ±lan STEP Ã§alÄ±ÅŸmalarÄ±nda ortalama kilo kaybÄ± yaklaÅŸÄ±k %15-17 arasÄ±nda raporlanmÄ±ÅŸtÄ± ğŸŸ¢ (STEP programÄ±, Ã§oklu RKÃ‡). Oral formun %13.6'lÄ±k sonucu biraz daha dÃ¼ÅŸÃ¼k olmakla birlikte, klinik aÃ§Ä±dan son derece anlamlÄ± bir deÄŸer. Ãœstelik oral formun <strong>hasta uyumunu artÄ±rma</strong> ve tedaviye <strong>daha erken baÅŸlanmasÄ±nÄ± saÄŸlama</strong> potansiyeli, bu kÃ¼Ã§Ã¼k farkÄ± fazlasÄ±yla telafi edebilir.</p>

    <h2 id="bolum-3">Ä°ÄŸneden Hapa: Neden Bu Kadar Ã–nemli?</h2>

    <p>Obezite tedavisinde GLP-1 ilaÃ§larÄ±nÄ±n en bÃ¼yÃ¼k engellerinden biri enjeksiyon gerekliliÄŸiydi. AraÅŸtÄ±rmalar, hastalarÄ±n Ã¶nemli bir kÄ±smÄ±nÄ±n yalnÄ±zca iÄŸne korkusu nedeniyle tedaviyi reddettiÄŸini veya erken bÄ±raktÄ±ÄŸÄ±nÄ± gÃ¶steriyor.</p>

    <div class="blog-box pink anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"/><line x1="12" y1="16" x2="12" y2="12"/><line x1="12" y1="8" x2="12.01" y2="8"/></svg>
      <div class="box-body">
        <strong>Oral Formun AvantajlarÄ±</strong>
        <ul>
          <li><strong>Ä°ÄŸne korkusu bariyeri azalÄ±yor:</strong> Ä°ÄŸne fobisi (tripanofobi) yetiÅŸkinlerin tahminen %10-20'sinde gÃ¶rÃ¼lmektedir ğŸŸ¡ (gÃ¶zlemsel Ã§alÄ±ÅŸmalar)</li>
          <li><strong>Oral uygulama:</strong> Sabah aÃ§ karnÄ±na, â‰¤120 mL su ile alÄ±nÄ±r; ardÄ±ndan en az 30 dakika yiyecek, iÃ§ecek veya diÄŸer oral ilaÃ§lardan kaÃ§Ä±nÄ±lmalÄ±dÄ±r. SoÄŸuk zincir veya enjeksiyon tekniÄŸi gerektirmez</li>
          <li><strong>Gizlilik:</strong> Ä°laÃ§ kullanÄ±mÄ± dÄ±ÅŸarÄ±dan fark edilmiyor; sosyal stigma azalÄ±yor</li>
          <li><strong>Birinci basamak uygunluÄŸu:</strong> Aile hekimleri daha rahat reÃ§ete yazabilir</li>
          <li><strong>Hasta uyumu:</strong> GÃ¼nlÃ¼k hap alÄ±ÅŸkanlÄ±ÄŸÄ± Ã§oÄŸu hasta iÃ§in zaten mevcut</li>
        </ul>
      </div>
    </div>

    <p>Oral Wegovy'nin "gÃ¼nde bir kez" alÄ±nmasÄ±, enjektabl formun "haftada bir kez" uygulamasÄ±yla karÅŸÄ±laÅŸtÄ±rÄ±ldÄ±ÄŸÄ±nda daha sÄ±k doz gerektiriyor. BirÃ§ok hasta iÃ§in her gÃ¼n bir hap almak, haftada bir kez enjeksiyondan daha kabul edilebilir bir rutin olabilir. Ancak oral formun aÃ§ karnÄ±na alÄ±nma ve 30 dakika bekleme gerekliliÄŸi, hasta uyumunu etkileyen bir faktÃ¶r olarak gÃ¶z Ã¶nÃ¼nde bulundurulmalÄ±dÄ±r.</p>

    <h2 id="bolum-4">GLP-1 Ä°laÃ§larÄ± KarÅŸÄ±laÅŸtÄ±rmasÄ±: Hap mÄ±, Ä°ÄŸne mi?</h2>

    <p>Piyasada ÅŸu an bulunan baÅŸlÄ±ca GLP-1 bazlÄ± kilo yÃ¶netimi seÃ§eneklerinin karÅŸÄ±laÅŸtÄ±rmasÄ±:</p>

    <table class="blog-table anim-slide-up">
      <thead>
        <tr><th>Ã–zellik</th><th>Oral Wegovy (Yeni)</th><th>Wegovy Enjeksiyon</th><th>Zepbound (Tirzepatid)</th></tr>
      </thead>
      <tbody>
        <tr><td>Etken madde</td><td>Oral semaglutid</td><td>Semaglutid 2.4 mg</td><td>Tirzepatid</td></tr>
        <tr><td>Uygulama</td><td>GÃ¼nlÃ¼k hap</td><td>HaftalÄ±k enjeksiyon</td><td>HaftalÄ±k enjeksiyon</td></tr>
        <tr><td>Kilo kaybÄ±</td><td>~%13.6 (64 hafta)</td><td>~%15-17 (68 hafta)</td><td>~%16-22 (72 hafta)</td></tr>
        <tr><td>Ä°ÄŸne gerekli mi?</td><td>âŒ HayÄ±r</td><td>âœ… Evet</td><td>âœ… Evet</td></tr>
        <tr><td>Mekanizma</td><td>GLP-1 RA</td><td>GLP-1 RA</td><td>GLP-1 + GIP Ã§ift agonist</td></tr>
        <tr><td>FDA onayÄ±</td><td>Åubat 2026</td><td>Haziran 2021</td><td>KasÄ±m 2023</td></tr>
      </tbody>
    </table>

    <p>WHO'nun yaptÄ±rdÄ±ÄŸÄ± Cochrane derlemeleri, GLP-1 sÄ±nÄ±fÄ±nÄ±n genel etkinliÄŸini net olarak ortaya koymuÅŸtur: <strong>tirzepatid ~%16, semaglutid ~%15, liraglutid ~%8</strong> ortalama kilo kaybÄ± ğŸŸ¢ (Cochrane sistematik derlemeleri, 2026). Oral semaglutid'in %13.6'lÄ±k sonucu, bu sÄ±nÄ±fÄ±n etkinlik aralÄ±ÄŸÄ±na tam olarak oturuyor.</p>

    <h2 id="bolum-5">Piyasada Ä°lk Ay: GÃ¼Ã§lÃ¼ Talep Sinyali</h2>

    <p>Novo Nordisk, Oral Wegovy'nin ABD'de 2026 baÅŸÄ±nda piyasaya sÃ¼rÃ¼lmesiyle birlikte gÃ¼Ã§lÃ¼ bir talep sinyali aldÄ±ÄŸÄ±nÄ± aÃ§Ä±kladÄ±. Ä°lk ay verileri, hem birinci basamak hekimler (PCP) hem de endokrinologlar arasÄ±nda hÄ±zlÄ± bir benimseme olduÄŸunu gÃ¶steriyor.</p>

    <div class="key-stat accent anim-slide-up">
      <span class="ks-num">ğŸš€</span>
      <span class="ks-text">Oral Wegovy, ABD'de lansman ayÄ±nda <strong>gÃ¼Ã§lÃ¼ bir ilk talep</strong> yakaladÄ±. Ã–zellikle daha Ã¶nce GLP-1 tedavisini enjeksiyon nedeniyle reddeden hasta popÃ¼lasyonunda yoÄŸun ilgi gÃ¶rÃ¼yor. Bu, oral GLP-1 pazarÄ±nÄ±n hÄ±zla bÃ¼yÃ¼yeceÄŸinin sinyali.</span>
    </div>

    <p>GlobeNewsWire'Ä±n 20 Åubat 2026 tarihli analizine gÃ¶re, ilk ay reÃ§ete verilerinde dikkat Ã§eken noktalar:</p>

    <ul>
      <li><strong>Birinci basamak hekimler aktif:</strong> Aile hekimlerinin oral formu reÃ§ete etmeye Ã§ok daha istekli olduÄŸu gÃ¶zlendi â€” enjeksiyon eÄŸitimi gerektirmemesi bÃ¼yÃ¼k avantaj</li>
      <li><strong>Yeni hasta kazanÄ±mÄ±:</strong> ReÃ§etelerin Ã¶nemli bir kÄ±smÄ± daha Ã¶nce hiÃ§ GLP-1 kullanmamÄ±ÅŸ hastalar iÃ§in yazÄ±ldÄ±</li>
      <li><strong>Enjeksiyondan geÃ§iÅŸ:</strong> Mevcut Wegovy enjeksiyon kullanan hastalarÄ±n bir kÄ±smÄ± oral forma geÃ§iÅŸ talep etti</li>
      <li><strong>Endokrinolog onayÄ±:</strong> Uzman hekimler de oral formu tedavi seÃ§eneklerine hÄ±zla dahil etti</li>
    </ul>

    <h3>Tedarik ve EriÅŸim EndiÅŸeleri</h3>

    <p>YÃ¼ksek talep, beraberinde tedarik sorunlarÄ± endiÅŸesini de getiriyor. Wegovy enjeksiyonun yaÅŸadÄ±ÄŸÄ± uzun sÃ¼reli arz kÄ±sÄ±tlÄ±klarÄ± hÃ¢lÃ¢ hafÄ±zalarda taze. Novo Nordisk, oral form iÃ§in Ã¼retim kapasitesini artÄ±rdÄ±ÄŸÄ±nÄ± ve tedarik zincirini gÃ¼Ã§lendirdiÄŸini belirtse de, talep artÄ±ÅŸÄ±nÄ±n sÃ¼rmesi halinde kÄ±sa vadeli arz sorunlarÄ± yaÅŸanabilir.</p>

    <h2 id="bolum-6">TÃ¼rkiye Ä°Ã§in Ne Anlama Geliyor?</h2>

    <p>TÃ¼rkiye, Avrupa'nÄ±n en yÃ¼ksek obezite oranlarÄ±ndan birine sahip ve etkili tedavi seÃ§eneklerine olan ihtiyaÃ§ kritik dÃ¼zeyde. Oral Wegovy'nin TÃ¼rkiye'ye gelmesi zaman alabilir, ancak bu geliÅŸme birÃ§ok aÃ§Ä±dan umut vaat ediyor.</p>

    <div class="blog-box success anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M22 11.08V12a10 10 0 11-5.93-9.14"/><polyline points="22 4 12 14.01 9 11.01"/></svg>
      <div class="box-body">
        <strong>TÃ¼rkiye Perspektifi</strong>
        <ul>
          <li><strong>RuhsatlandÄ±rma sÃ¼reci:</strong> FDA onayÄ±, TÃ¼rk Ä°laÃ§ ve TÄ±bbi Cihaz Kurumu (TÄ°TCK) iÃ§in Ã¶nemli bir referans. Ancak ayrÄ± bir deÄŸerlendirme sÃ¼reci gerekiyor</li>
          <li><strong>Mevcut durum:</strong> TÃ¼rkiye'de semaglutid enjeksiyonu (Ozempic) eriÅŸimde arz sÄ±kÄ±ntÄ±larÄ± yaÅŸanÄ±yor. Oral form, Ã¼retim Ã¶lÃ§eklendikÃ§e eriÅŸimi kolaylaÅŸtÄ±rabilir</li>
          <li><strong>SGK kapsamÄ±:</strong> Maliyet ve geri Ã¶deme politikasÄ±, oral formun TÃ¼rkiye'deki yaygÄ±nlÄ±ÄŸÄ±nÄ± belirleyecek en kritik faktÃ¶r</li>
          <li><strong>Birinci basamak entegrasyonu:</strong> Oral form, aile saÄŸlÄ±ÄŸÄ± merkezlerinde obezite tedavisinin baÅŸlatÄ±lmasÄ±nÄ± kolaylaÅŸtÄ±rabilir</li>
        </ul>
      </div>
    </div>

    <p>Oral GLP-1 ilaÃ§larÄ±nÄ±n geliÅŸimi sadece Wegovy ile sÄ±nÄ±rlÄ± deÄŸil. Pfizer, AstraZeneca ve Eli Lilly gibi bÃ¼yÃ¼k ilaÃ§ firmalarÄ± da oral GLP-1 programlarÄ±nÄ± hÄ±zla ilerletiyor. Bu rekabet, fiyatlarÄ±n dÃ¼ÅŸmesine ve eriÅŸimin artmasÄ±na katkÄ± saÄŸlayacak. Ã–zellikle AstraZeneca'nÄ±n elecoglipron'u Faz 2'yi geÃ§erek Faz 3'e ilerledi; Eli Lilly'nin orforglipron'u da gÃ¼Ã§lÃ¼ Faz 3 verileri aÃ§Ä±kladÄ±.</p>

    <h2 id="bolum-7">SonuÃ§: Obezite Tedavisinde Yeni Bir Sayfa</h2>

    <p>Oral Wegovy'nin FDA onayÄ±, obezite tedavisinde tedavi seÃ§eneklerinin geniÅŸlediÄŸini gÃ¶stermektedir. GLP-1 reseptÃ¶r agonistlerinin etkinliÄŸi meta-analizler ve Cochrane incelemeleri ile gÃ¼Ã§lÃ¼ ÅŸekilde desteklenmiÅŸtir. Ancak kritik soru ÅŸu: <strong>Bu tedaviye herkes eriÅŸebilecek mi?</strong></p>

    <p>Oral form, bu sorunun yanÄ±tÄ±na bÃ¼yÃ¼k katkÄ± saÄŸlÄ±yor. Ä°ÄŸne bariyerini ortadan kaldÄ±rarak, birinci basamaÄŸa entegrasyonu kolaylaÅŸtÄ±rarak ve hasta uyumunu artÄ±rarak, GLP-1 tedavisinin eriÅŸim alanÄ±nÄ± geniÅŸletiyor. Ancak maliyet, tedarik ve sigorta kapsamÄ± gibi yapÄ±sal engeller hÃ¢lÃ¢ Ã§Ã¶zÃ¼lmeyi bekliyor.</p>

    <div class="blog-takeaway anim-slide-up">
      <h4>ğŸ“Œ Ana Ã‡Ä±karÄ±mlar</h4>
      <ul>
        <li>Oral Wegovy, FDA tarafÄ±ndan onaylanan ilk GLP-1 kilo verme hapÄ± â€” enjeksiyon dÃ¶nemi sona eriyor</li>
        <li>OASIS 4 Ã§alÄ±ÅŸmasÄ±nda 64 haftada ortalama %13.6 kilo kaybÄ± â€” klinik olarak anlamlÄ± ve gÃ¼venli</li>
        <li>GÃ¼nde 1 hap, haftada 1 enjeksiyonun yerini alÄ±yor; hasta uyumu ve eriÅŸim artÄ±yor</li>
        <li>ABD'de ilk ay gÃ¼Ã§lÃ¼ talep: hem birinci basamak hem uzman hekimler hÄ±zla benimsedi</li>
        <li>WHO/Cochrane verileri GLP-1 sÄ±nÄ±fÄ±nÄ±n etkinliÄŸini doÄŸruluyor: tirzepatid ~%16, semaglutid ~%15, liraglutid ~%8</li>
        <li>TÃ¼rkiye'ye gelmesi zaman alacak, ancak oral form uzun vadede eriÅŸimi demokratikleÅŸtirebilir</li>
        <li>Rekabet artÄ±yor: AstraZeneca, Pfizer, Eli Lilly de oral GLP-1 programlarÄ± geliÅŸtiriyor â€” fiyat dÃ¼ÅŸÃ¼ÅŸÃ¼ bekleniyor</li>
      </ul>
    </div>

    <div class="blog-box warning anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M10.29 3.86L1.82 18a2 2 0 001.71 3h16.94a2 2 0 001.71-3L13.71 3.86a2 2 0 00-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>
      <div class="box-body">
        <strong>âš ï¸ TÄ±bbi UyarÄ±</strong>
        <p>Bu yazÄ±daki bilgiler yalnÄ±zca eÄŸitim ve bilgilendirme amaÃ§lÄ±dÄ±r. GLP-1 reseptÃ¶r agonistleri reÃ§eteye tabi ilaÃ§lardÄ±r. Oral Wegovy dahil tÃ¼m GLP-1 ilaÃ§larÄ± yalnÄ±zca doktor gÃ¶zetiminde kullanÄ±lmalÄ±dÄ±r. Herhangi bir tedavi kararÄ± almadan Ã¶nce <strong>mutlaka doktorunuza danÄ±ÅŸÄ±n</strong>. Kendi baÅŸÄ±nÄ±za ilaÃ§ kullanmaya baÅŸlamayÄ±n veya mevcut tedavinizi deÄŸiÅŸtirmeyin.</p>
      </div>
    </div>

  </div>

  <!-- Social Sharing -->
  <div class="blog-share">
    <span>PaylaÅŸ:</span>
    <a class="share-btn" href="https://twitter.com/intent/tweet?url=https://uzunyasa.com/pages/blog/oral-wegovy-fda-onayi-ilk-glp1-hapi.html&text=Oral%20Wegovy%20FDA%20Onay%C4%B1%3A%20%C4%B0lk%20GLP-1%20Kilo%20Verme%20Hap%C4%B1%20Piyasada!" target="_blank" rel="noopener" aria-label="Twitter'da paylaÅŸ">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"/></svg>
    </a>
    <a class="share-btn" href="https://www.linkedin.com/sharing/share-offsite/?url=https://uzunyasa.com/pages/blog/oral-wegovy-fda-onayi-ilk-glp1-hapi.html" target="_blank" rel="noopener" aria-label="LinkedIn'de paylaÅŸ">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433a2.062 2.062 0 01-2.063-2.065 2.064 2.064 0 112.063 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"/></svg>
    </a>
    <a class="share-btn" href="https://wa.me/?text=Oral%20Wegovy%20FDA%20Onay%C4%B1%3A%20%C4%B0lk%20GLP-1%20Kilo%20Verme%20Hap%C4%B1%20https://uzunyasa.com/pages/blog/oral-wegovy-fda-onayi-ilk-glp1-hapi.html" target="_blank" rel="noopener" aria-label="WhatsApp'ta paylaÅŸ">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M17.472 14.382c-.297-.149-1.758-.867-2.03-.967-.273-.099-.471-.148-.67.15-.197.297-.767.966-.94 1.164-.173.199-.347.223-.644.075-.297-.15-1.255-.463-2.39-1.475-.883-.788-1.48-1.761-1.653-2.059-.173-.297-.018-.458.13-.606.134-.133.298-.347.446-.52.149-.174.198-.298.298-.497.099-.198.05-.371-.025-.52-.075-.149-.669-1.612-.916-2.207-.242-.579-.487-.5-.669-.51-.173-.008-.371-.01-.57-.01-.198 0-.52.074-.792.372-.272.297-1.04 1.016-1.04 2.479 0 1.462 1.065 2.875 1.213 3.074.149.198 2.096 3.2 5.077 4.487.709.306 1.262.489 1.694.625.712.227 1.36.195 1.871.118.571-.085 1.758-.719 2.006-1.413.248-.694.248-1.289.173-1.413-.074-.124-.272-.198-.57-.347m-5.421 7.403h-.004a9.87 9.87 0 01-5.031-1.378l-.361-.214-3.741.982.998-3.648-.235-.374a9.86 9.86 0 01-1.51-5.26c.001-5.45 4.436-9.884 9.888-9.884 2.64 0 5.122 1.03 6.988 2.898a9.825 9.825 0 012.893 6.994c-.003 5.45-4.437 9.884-9.885 9.884m8.413-18.297A11.815 11.815 0 0012.05 0C5.495 0 .16 5.335.157 11.892c0 2.096.547 4.142 1.588 5.945L.057 24l6.305-1.654a11.882 11.882 0 005.683 1.448h.005c6.554 0 11.89-5.335 11.893-11.893a11.821 11.821 0 00-3.48-8.413z"/></svg>
    </a>
  </div>

  <!-- Author Box -->
  <div class="blog-author anim-slide-up">
    <div class="blog-author-avatar">UY</div>
    <div class="blog-author-info">
      <h4>UzunYaÅŸa EditÃ¶ryal Ekibi</h4>
      <p>Obezite tedavisi ve GLP-1 ilaÃ§larÄ± konusunda gÃ¼ncel bilimsel geliÅŸmeleri takip ediyoruz.</p>
    </div>
  </div>

  <!-- CTA -->
  <div class="blog-cta anim-slide-up">
    <h3>SaÄŸlÄ±k deÄŸerlendirmenizi yapÄ±n</h3>
    <p>KiÅŸiselleÅŸtirilmiÅŸ saÄŸlÄ±k Ã¶nerileri iÃ§in Ã¼cretsiz testimizi tamamlayÄ±n</p>
    <a href="../test.html">Teste BaÅŸla &rarr;</a>
  </div>

  <!-- Related Posts -->
  <div class="blog-related anim-slide-up">
    <h3>Ä°lgili YazÄ±lar</h3>
    <div class="related-grid">
      <a href="glp1-tam-rehber.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>GLP-1 Ä°laÃ§larÄ± Tam Rehberi: Ozempic, Wegovy, Mounjaro</h4>
          <p>18 dk okuma</p>
        </div>
      </a>
      <a href="oral-glp1-orforglipron-igneden-hapa.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1585435557343-3b092031a831?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>Oral GLP-1 Devrimi: Orforglipron ile Ä°ÄŸneden Hapa GeÃ§iÅŸ</h4>
          <p>12 dk okuma</p>
        </div>
      </a>
      <a href="who-cochrane-glp1-incelemesi.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1532187863486-abf9dbad1b69?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>WHO Cochrane Ä°ncelemesi: GLP-1 Ä°laÃ§larÄ± Ne Kadar Etkili?</h4>
          <p>12 dk okuma</p>
        </div>
      </a>
    </div>
  </div>

  <!-- Newsletter -->
  <div class="blog-newsletter anim-slide-up">
    <h3>SaÄŸlÄ±k BÃ¼ltenimize KatÄ±lÄ±n</h3>
    <p>HaftanÄ±n en Ã¶nemli saÄŸlÄ±k haberleri ve bilimsel geliÅŸmeleri e-postanÄ±za gelsin.</p>
    <form class="newsletter-form" onsubmit="return false;">
      <input type="email" placeholder="E-posta adresiniz" required>
      <button type="submit">Abone Ol</button>
    </form>
  </div>

  <!-- Disclaimer -->
  <div class="blog-disclaimer">
    <strong>Yasal UyarÄ±:</strong> Bu yazÄ± bilgilendirme amaÃ§lÄ±dÄ±r ve tÄ±bbi tavsiye niteliÄŸi taÅŸÄ±maz.
    GLP-1 reseptÃ¶r agonistleri reÃ§eteye tabi ilaÃ§lardÄ±r. Tedavi kararlarÄ± iÃ§in mutlaka bir saÄŸlÄ±k profesyoneline danÄ±ÅŸÄ±n.
    <br><br>
    <strong>Kaynaklar:</strong><br>
    1. AJMC. "FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss." Åubat 2026. <a href="https://www.ajmc.com/view/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss" target="_blank" rel="noopener">ajmc.com</a><br>
    2. Applied Clinical Trials. "FDA Approves Oral Wegovy â€” Positive OASIS Trial Results." Åubat 2026. <a href="https://www.appliedclinicaltrialsonline.com/view/fda-approves-oral-wegovy-positive-oasis-trial-results" target="_blank" rel="noopener">appliedclinicaltrialsonline.com</a><br>
    3. GlobeNewsWire. "Novo Nordisk's Wegovy Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity." 20 Åubat 2026. <a href="https://www.globenewswire.com/news-release/2026/02/20/3241885/0/en/Novo-Nordisk-s-Wegovy-Pill-Achieves-Strong-First-Month-Uptake-Signaling-Expanding-Demand-for-Oral-GLP-1s-in-Obesity.html" target="_blank" rel="noopener">globenewswire.com</a><br>
    4. WHO/Cochrane Systematic Reviews â€” GLP-1 Receptor Agonist Efficacy Data.<br>
    5. OASIS 4 â€” Oral Semaglutide Phase 3 Clinical Trial.
  </div>

</article>

<!-- FOOTER -->
<footer class="footer">
  <div class="footer-inner">
    <div class="footer-grid">
      <div class="footer-brand">
        <img src="/images/logo-new.png" alt="UzunYaÅŸa" class="footer-logo">
        <p>TÃ¼rkiye uzun yaÅŸasÄ±n diye. KanÄ±ta dayalÄ± saÄŸlÄ±k bilgisi ve araÃ§larÄ±.</p>
      </div>
      <div class="footer-col">
        <h4>KeÅŸfet</h4>
        <a href="../beslenme.html">Beslenme</a>
        <a href="../egzersiz.html">Egzersiz</a>
        <a href="../tedavi.html">Kilo YÃ¶netimi</a>
        <a href="../uyku-stres.html">Zihin &amp; DavranÄ±ÅŸ</a>
      </div>
      <div class="footer-col">
        <h4>AraÃ§lar</h4>
        <a href="../araclar.html">TÃ¼m AraÃ§lar</a>
        <a href="../test.html">KiÅŸisel Test</a>
        <a href="../blog.html">Blog</a>
      </div>
      <div class="footer-col">
        <h4>HakkÄ±mÄ±zda</h4>
        <a href="../hakkimizda.html">Ekibimiz</a>
        <a href="../bilim.html">Bilim</a>
        <a href="https://tyzd.org" target="_blank">TYZD</a>
      </div>
    </div>
    <div class="footer-bottom">
      <span>&copy; 2026 UzunYaÅŸa. <a href="https://tyzd.org" target="_blank" style="color:inherit;text-decoration:underline;">TÄ±pta Yapay Zeka DerneÄŸi</a> giriÅŸimidir.</span>
      <span style="font-size:0.8rem;opacity:0.5;">Bu site tÄ±bbi tavsiye sunmaz. Tedavi iÃ§in doktorunuza danÄ±ÅŸÄ±n.</span>
    </div>
  </div>
</footer>

<!-- Scripts -->
<script>
// Reading Progress Bar
window.addEventListener('scroll', () => {
  const article = document.querySelector('.blog-article');
  if (!article) return;
  const rect = article.getBoundingClientRect();
  const total = article.scrollHeight - window.innerHeight;
  const scrolled = -rect.top;
  const pct = Math.min(Math.max(scrolled / total * 100, 0), 100);
  document.getElementById('blogProgress').style.width = pct + '%';
});

// Scroll Animation Observer
const observer = new IntersectionObserver((entries) => {
  entries.forEach(e => {
    if (e.isIntersecting) {
      e.target.classList.add('anim-visible');
      observer.unobserve(e.target);
    }
  });
}, { threshold: 0.15 });

document.querySelectorAll('.anim-slide-up').forEach(el => {
  if (!el.classList.contains('anim-visible')) observer.observe(el);
});

// Header scroll effect
window.addEventListener('scroll', () => {
  const header = document.querySelector('.header');
  if (window.scrollY > 60) {
    header.classList.add('scrolled');
  } else {
    header.classList.remove('scrolled');
  }
});
</script>
<script src="../../scripts/animations.js" defer></script>
<script src="/scripts/premium-animations.js" defer></script>
</body>
</html>